Cord Blood Stem Cells – A Global Market Overview

20 Oct 2011 • by Natalie Aster

Research students from Johns Hopkins have evolved a new method that offers the potential to considerably increase cord blood stem cells collection post birth. This innovation, called CBx System, is undergoing testing, though the students have been successful in obtaining a provisional patent for the technology and formed a company called TheraCord LLC, with the hope that it would be of wide usage in hospital maternity wards in future.

Cord blood offers great potential for treating and curing several diseases, though it is usually not collected and discarded after birth. A major reason for this is that a viable collection method does not exist and this leads to wastage of valuable cord blood.

Currently, when a baby is born, parents have the option of cord blood collection and storage, which involves expense or they can donate cord blood at one of 180 hospitals that are affiliated with public cord blood banks.

At present, about 40-50% of units collected can be used for transplants and the stem cells are usually only enough for a child. The newly developed method uses gravity in the collection process that combines mechanical forces and a chemical solution that can detach and flush more stem cells from the cord and placenta vessels, even up to 50% more stem cells.

The report “Cord Blood Stem Cells – A Global Market Overview” by Industry Experts reviews and projects the cord blood stem cells market for global and the regional markets including North America, Europe, Asia-Pacific and Rest of World. Cord blood stem cell technologies analyzed in the study include Stem Cell Transplant, Cord Blood Banking, Blood Transfusion, Cell Based Genetics and Xenotransplant. The report analyses the global market for stem cell therapeutic areas comprising Neurology, Oncology, Cardiology, Cartilage, Blood Disorders, Diabetes, Dermatology and Other.

Report Details:

Cord Blood Stem Cells – A Global Market Overview
Published: October 2011
Pages: 282
Price: US$ 4,320.00 US$ 4,050.00

Report Sample Abstract


JUNE 2011. Cord Blood America Takes Over Assets of NeoCells

Cord Blood America, Inc, an umbilical cord blood stem cell preservation company, took over the assets of Evanston, Illinois-based NeoCells, a subsidiary of ViviCells International, Inc for a consideration of US$320,000. This deal enables Cord Blood America to add over 2,700 customers to its client base through acquisitions that included the February takeover of all the umbilical cord blood samples from Reproductive Genetics Institute, Inc. The customers’ umbilical cord blood stem cells that were saved at birth have been moved to the company’s Las Vegas headquarters.

BioLife Solutions Leads in Supply of Cryopreservation Media for Stem Cells

BioLife Solutions Inc, engaged in developing, manufacturing and marketing patented hypothermic storage, transport and cryopreservation (freezing) media for cells, tissues and organs, has gained leadership position in the supply of pre-formulated GMP cryopreservation media for umbilical cord blood stem cells. The company offers its products to research facilities, hospitals and companies that engage in cell therapy, tissue engineering, cord blood banking, toxicology testing and drug discovery.

BioLife has cornered a considerable market share by enhancing relationships with direct and indirect customers such as Community Blood Services and China Cord Blood Bank via contract manufacturing customer OriGen Biomedical. The company is also being assisted by several contract banking services customers, such as ViaCord, Lifeforce Cryobanks and New England Cord Blood Bank. The past two years have enabled the company to gain leading position with its GMP grade CryoStor and BloodStor stem cell freeze media products.

JULY 2011. Cord Blood America in an Agreement with Regence

Cord Blood America, Inc and Regence entered into an agreement for offering storage of umbilical cord blood to members of its BlueCross and BlueShield plans in Idaho, Oregon, Utah and Washington at discounted rates in line with its other BlueCross BlueShield (BCBS) licensee contracts. The collaboration enables Regence members thinking about cord blood banking to gain discounts on CorCell's Saving Baby's Cord Blood program. Cord Blood America’s association with BlueCross BlueShield programs all over the country has provided several benefits to members, in addition to making the company expand.

More information can be found in the report “Cord Blood Stem Cells – A Global Market Overview” by Industry Experts.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970